Precision Biosciences Inc (DTIL)
Precision BioSciences develops gene editing treatments for genetic and infectious diseases using its ARCUS platform. It last closed at $6.95 on Nov 2. DTIL reports earnings on Tue, Nov 3, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From DTIL's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 6). Last 12 months adds up the four latest quarters.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 3 | HC Wainwright & Co. | Reiterated | Buy | $60 |
| Jun 9 | Oppenheimer | Initiated | Buy | $20 |
| May 27 | HC Wainwright & Co. | Reiterated | Buy | $60 |
Technical Analysis
The stock is 6% above its 20 day and 1% above its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 54). The nearest support is the 50 day average at $6.86, and the nearest resistance the Pivot at $7.01.
| RSI (14) | 53.90 | Middle of its range | Neutral |
| MACD | 0.12 | Above its signal line | Bullish |
| Stochastic | 68.1 | Middle of its range | Neutral |
| ADX (14) | 15.2 | No clear trend | |
| Williams %R | -41.4 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 92.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +12.3% | Change over 10 sessions | Bullish |
| ATR (14) | $0.44 | Typical daily range, 6.3% of price |
| RSI (14) | 50.90 | Middle of its range | Neutral |
| MACD | 0.01 | Below its signal line | Bearish |
| Stochastic | 32.1 | Middle of its range | Neutral |
| ADX (14) | 31.5 | Trending up | |
| Williams %R | -66.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -31.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −10.7% | Change over 10 sessions | Bearish |
| ATR (14) | $1.00 | Typical daily range, 14.4% of price |
What happened before
See how DTIL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DTIL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in DTIL in the last 90 days.
DTIL Institutional Ownership
Hedge fund holdings →| # | Fund | Shares | Of company | Value | Change | |
|---|---|---|---|---|---|---|
| 1 | Aberdeen Group plc | 2.2M | 8.08% | $17.5M | 0 | No change |
| 2 | Bleichroeder LP | 2M | 7.31% | $15.9M | +356K | Added |
| 3 | Octagon Capital Advisors LP | 1.4M | 4.89% | $10.6M | −887K | Trimmed |
| 4 | Boothbay Fund Management, LLC | 1.3M | 4.88% | $10.6M | +280K | Added |
| 5 | BlackRock, Inc. | 1.2M | 4.25% | $9.2M | +973K | Added |
| 6 | Vanguard Capital Management LLC | 1.1M | 4.04% | $8.8M | +206K | Added |
| 7 | Lynx1 Capital Management LP | 950K | 3.44% | $7.5M | −35K | Trimmed |
| 8 | Driehaus Capital Management LLC | 947K | 3.43% | $7.4M | −49K | Trimmed |
| 9 | Empery Asset Management, LP | 776K | 2.81% | $6.1M | −1.2M | Trimmed |
| 10 | Affinity Asset Advisors, LLC | 647K | 2.34% | $5.1M | +49K | Added |
| 11 | Geode Capital Management, LLC | 621K | 2.25% | $4.9M | +334K | Added |
| 12 | Mackenzie Financial Corp | 481K | 1.74% | $3.8M | +481K | New |
| 13 | State Street Corp | 427K | 1.55% | $3.4M | +354K | Added |
| 14 | Acadian Asset Management LLC | 306K | 1.11% | $2K | +261K | Added |
| 15 | ArrowMark Colorado Holdings LLC | 274K | 0.99% | $2.2M | +95K | Added |
| 16 | Corient Private Wealth LP | 245K | 0.89% | $1.9M | +101K | Added |
| 17 | Two Sigma Investments, LP | 238K | 0.86% | $1.9M | −70K | Trimmed |
| 18 | Northern Trust Corp | 190K | 0.69% | $1.5M | +114K | Added |
| 19 | Jpmorgan Chase & Co | 180K | 0.65% | $1.4M | +180K | Added |
| 20 | Vanguard Fiduciary Trust Co | 167K | 0.60% | $1.3M | +11K | Added |
| 21 | Vanguard Portfolio Management LLC | 162K | 0.59% | $1.3M | +162K | New |
| 22 | Goldman Sachs Group Inc | 140K | 0.51% | $1.1M | +100K | Added |
| 23 | Squarepoint Ops LLC | 137K | 0.50% | $1.1M | +93K | Added |
| 24 | Morgan Stanley | 131K | 0.47% | $1.0M | +8,259 | Added |
| 25 | Commonwealth Equity Services, LLC | 116K | 0.42% | $911K | +3,258 | Added |
- BlackRock, Inc.+973K sh$7.6M
- Mackenzie Financial Corp+481K sh$3.8M
- Bleichroeder LP+356K sh$2.8M
- State Street Corp+354K sh$2.8M
- Geode Capital Management, LLC+334K sh$2.6M
- Boothbay Fund Management, LLC+280K sh$2.2M
- Empery Asset Management, LP−1.2M sh−$9.4M
- Octagon Capital Advisors LP−887K sh−$7.0M
- Marshall Wace, LLP−416K sh−$2.3M
- Renaissance Technologies LLC−155K sh−$1.2M
- Alyeska Investment Group, L.P.−139K sh−$764K
- Two Sigma Investments, LP−70K sh−$550K
- Mackenzie Financial CorpTrimmed−245K shNov 2
- China Universal Asset Management Co., Ltd.Trimmed−12K shOct 28
- NFSG CorpSold out−1,600 shOct 15
- Nisa Investment Advisors, LLCSold out−1,400 shOct 20
- Commonwealth Equity Services, LLCAdded+1,165 shNov 2
- SBI Securities Co., Ltd.Trimmed−300 shOct 22
- GAMMA Investing LLCNew+260 shOct 8
- SJS Investment Consulting Inc.New+104 shOct 26
From SEC Form 13F filings by funds managing over $100 million, as of Jun 30, 2026. Changes compare each fund with its own Q1 2026 filing. "Held by funds" adds up the shares every 13F filer reported, over shares outstanding. Filings come up to 45 days after the quarter ends. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DTIL is in one of them and how their past DTIL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DTIL in an article yet. Here's the latest on the wider market.
About Precision Biosciences
Precision BioSciences is a gene editing company based in Durham, North Carolina. It uses its ARCUS platform, a gene editing tool built on a single protein, to develop treatments for genetic and infectious diseases. Its lead programs target chronic hepatitis B and Duchenne muscular dystrophy, and it also partners with iECURE on a treatment for ornithine transcarbamylase deficiency. The company's work is aimed at patients with these serious conditions.
- Headquarters
- Durham, NC